

Baxter Healthcare Corporation
 New Prescription Drug Launch; Exceeds Medicare Part D Threshold
 Attention: Office of the Vermont Attorney General
 Send To: AGO.highcostprescriptiondrugs@vermont.gov

1	2	3	4	5	6
Line No.	NDC*	Drug Product Description	Introduced to Market Date*	WAC at Intro to Market*	Marketing/Pricing Plan Description

1	10019-0079-01	Bendamustine HCl Injection	2/8/2023	2340	Baxter's contractual manufacturing agreements are business confidential
---	---------------	----------------------------	----------	------	---

7	8	9	10	11	12	13	14
Marketing/Pricing Plan Non-Pub Ind	Estimated Number of Patients	Breakthrough Therapy?	Priority Review?	Acquisition Date	Acquisition Price	Acquisition Price Non-Pub Ind	Acquisition Price Comment

1000 / yr.

No

N/A

N/A

N/A

N/A

N/A

General	NDC
Comments	

10019007901